Document Detail


XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
MedLine Citation:
PMID:  23299794     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: Genetic variations are related to individual differences of DNA repair ability and drug metabolism, which can greatly influence prognosis of antineoplastic agents, such as oxaliplatin. The aim was to explore the influences of X-ray repair cross-complementing 1(XRCC1) and Glutathione S-transferase P1 (GSTP1) genetic variants on prognosis of oxaliplatin-based chemotherapy in colorectal cancer patients. METHODS: We performed a meta-analysis including 13 original studies with a total number of 1,234 patients in advanced or metastatic colorectal cancer. Tumor responses [complete response, partial response, stable disease (SD) and progressive disease (PD)] and progression-free survival were estimated. RESULTS: Our results showed that XRCC1 Arg399Gln polymorphism was significantly associated with tumor chemotherapy when SD or PD was considered as non-response [risk ratio (RR) = 1.29; 95 % confidence intervals (CI): 1.05-1.60; P = 0.02]. No significant association was found between GSTP1 Ile105 Val polymorphism and tumor response (RR = 0.63; 95 % CI: 0.35-1.14; P = 0.13). In addition, our results also showed that there was no significant association between XRCC1 codon 399 Arg/Gln or Gln/Gln genotypes and hazard ratio for progression-free survival (Hazards ratio = 1.04 and 1.92; 95 % CI: 0.75-1.43 and 0.62-1.37; P = 0.826 and 0.677, respectively). CONCLUSION: In our meta-analysis, XRCC1 Arg399Gln polymorphism may be a valuable genetic marker for oxaliplatin-based chemotherapy in colorectal cancer, and the results still need further confirmation.
Authors:
Fanghui Ye; Zhenfang Liu; Aihua Tan; Ming Liao; Zengnan Mo; Xiaobo Yang
Related Documents :
24281164 - The prognostic value of haplotypes in the vascular endothelial growth factor a gene in ...
23729494 - Changes in indications and oncological outcomes of radical prostatectomy after 2000--da...
21738564 - Correction: a new crocodylian from the late maastrichtian of spain: implications for th...
7822394 - Long-term results of core decompression for ischaemic necrosis of the femoral head.
9632274 - Peripheral blood stem cell autografts for the treatment of children over 1 year old wit...
11505404 - Phase ii study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as fir...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-9
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  -     ISSN:  1432-0843     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Principles of dose finding studies in cancer: a comparison of trial designs.
Next Document:  The energy cost of shuttle running.